Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism

Table 2 The efficacy and safety outcomes between rivaroxaban and LMWH by unmatched-, PSM-, and competing risk analysis at 12 months

Outcomes^a	Unmatched population				Propensity score-matched population				Competing risk^b
	Rivaroxaban No. (%) (N = 216)	LMWH No. (%) (N = 230)	HR (95% CI)	P value	Rivaroxaban No. (%) (N = 191)	LMWH No. (%) (N = 191)	HR (95% CI)	P value	SHR (95% CI)	P value
Primary outcomes^a
Composite outcome	33 (15.3)	43 (18.7)	0.71 (0.45–1.12)	0.14	29 (15.2)	34 (17.8)	0.73 (0.45–1.21)	0.22	0.83 (0.51–1.37)	0.47
All-cause mortality	52 (24.1)	88 (38.3)	0.54 (0.39–0.77)	< 0.001	47 (24.6)	77 (40.3)	0.52 (0.36–0.75)	< 0.001	0.54 (0.38–0.78)	< 0.001
Secondary outcomes^a
VTE recurrence	18 (8.3)	25 (10.9)	0.67 (0.37–1.23)	0.20	16 (8.4)	20 (10.5)	0.69 (0.36–1.34)	0.28	0.79 (0.41–1.52)	0.47
PE	10 (4.6)	14 (6.1)	0.65 (0.29–1.47)	0.30	9 (4.7)	11 (5.8)	0.70 (0.29–1.69)	0.42	0.81 (0.34–1.95)	0.64
DVT	8 (3.7)	11 (4.8)	0.69 (0.28–1.73)	0.43	7 (3.7)	9 (4.7)	0.69 (0.26–1.86)	0.46	0.77 (0.29–2.06)	0.60
Major bleeding	15 (6.9)	18 (7.8)	0.77 (0.39–1.53)	0.45	13 (6.8)	14 (7.3)	0.79 (0.37–1.68)	0.54	0.92 (0.44–1.96)	0.84
CRNMB	28 (13.0)	22 (9.6)	1.17 (0.67–2.04)	0.59	24 (12.6)	18 (9.4)	1.13 (0.62–2.09)	0.69	1.36 (0.74–2.5)	0.33

Abbreviations: LMWH low-molecular-weight heparin, PSM propensity score matching, VTE venous thromboembolism, PE pulmonary embolism, DVT deep vein thrombosis, CRNMB clinically relevant non-major bleeding, SHR subdistribution hazard ratio, CI Confidence interval
^aThe first event after the index date was identified as the final outcome for patients diagnosed with more than one event
^bEvaluated by the Fine and Gray proportional subdistribution hazard model considering death as a competing risk in the matched cohorts

ISSN: 1477-9560